Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Product sales	$ 2,963,411	$ 2,135,197	$ 7,887,377	$ 5,977,202
Cost of product sales	1,095,724	920,935	2,980,965	2,564,775
Gross profit	1,867,687	1,214,262	4,906,412	3,412,427
Operating expenses
Research and development	293,093	496,874	898,451	1,600,144
Sales and marketing	488,688	816,025	1,547,087	2,399,131
General and administrative	1,118,251	1,039,223	3,298,461	3,637,333
Total operating expenses	1,900,032	2,352,122	5,743,999	7,636,608
Operating loss	(32,345)	(1,137,860)	(837,587)	(4,224,181)
Other income (expenses), net
Interest income	103	30	227	2,394
Loss on disposal of property and equipment	0	(1,213)	0	(1,213)
Interest expense	(1,077)	(33,334)	(188,992)	(41,667)
Amortization of debt discount	0	(93,598)	(155,996)	(124,797)
Write-off of deferred financing costs	(67,664)	0	(67,664)	(86,736)
Loss from equity-method investment in SAVSU	(217,735)	0	(707,208)	0
Total other income (expenses), net	(286,373)	(128,115)	(1,119,633)	(252,019)
Net loss	(318,718)	(1,265,975)	(1,957,220)	(4,476,200)
Net loss attributable to non-controlling interest	0	296,974	0	924,288
Net loss attributable to BioLife Solutions, Inc.	(318,718)	(969,001)	(1,957,220)	(3,551,912)
Less: Preferred stock dividends	(106,250)	0	(106,250)	0
Net loss attributable to common stockholders	$ (424,968)	$ (969,001)	$ (2,063,470)	$ (3,551,912)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share)	$ (0.03)	$ (0.08)	$ (0.16)	$ (0.28)
Basic and diluted weighted average common shares used to calculate net loss per common share (in shares)	13,238,248	12,699,419	13,102,238	12,575,560